Cover image

Nanotheranostics, the sister journal of Theranostics, is a multidisciplinary and fully open access journal. Currently, the journal does not charge any publication or submission fees (Platinum open access). Nanotheranostics publishes innovative and original basic, translational and clinical research reflecting the fields of nanomedicine, nanoimaging, drug and gene delivery, nanoelectronic biosensors, and other areas. 

Regular features include high quality research articles, reviews or mini-reviews, rapid communication of preliminary data on innovative research, editorials, and letters to the editor. Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical studies or ethical issues of nanomedicine are also welcome. Timely reviews that provide updates on current applications and issues in nanomedicine and translational aspects of nanotheranostics and other topics are particularly welcome and will be given high priority.

Nanotheranostics employs a rigorous peer-review system, but also strives for rapid review turnaround times and is based on the same streamlined submission platform as Theranostics.

Recent Papers:


Graphic abstract

Research Paper
Development and In vivo Pharmacokinetic and Pharmacodynamic Evaluation of an Oral Innovative Cyclodextrin Complexed Lipid Nanoparticles of Irbesartan Formulation for Enhanced Bioavailability
Narendar Dudhipala, Swetha Ettireddy, Ahmed Adel Ali Youssef, Goverdhan Puchchakayala
Nanotheranostics 2023; 7(1): 117-127. doi:10.7150/ntno.78102
[Abstract] [Full text] [PDF]


Graphic abstract

Research Paper
Development of a Personalised Device for Systemic Magnetic Drug Targeting to Brain Tumours
Priya Patel, Areej Alghamdi, Gary Shaw, Christopher Legge, Maggie Glover, Danielle Freeman, Harry Hodgetts, Erica Wilson, Faith Howard, Sarah Staniland, Aneurin J Kennerley, Duncan Wood, Robert Moorehead, Charlotte Hadfield, Ola Rominiyi, Jon Griffin, Spencer J Collis, Sam Hyde, Marcus Crossley, Martyn Paley, Munitta Muthana
Nanotheranostics 2023; 7(1): 102-116. doi:10.7150/ntno.76559
[Abstract] [Full text] [PDF]


Graphic abstract

Research Paper
Pre-clinical Investigations of Therapeutic Markers Associated with Acute and Chronic Restraint Stress: A Nuclear Magnetic Resonance Based Contrast Metabolic Approach
Sanjay Singh, Sukanya Tripathy, Atul Rawat, Durgesh Dubey, Sarfraj Ahmad Siddiqui, Rajesh Ugale, Dinesh Kumar, Anand Prakash
Nanotheranostics 2023; 7(1): 91-101. doi:10.7150/ntno.76294
[Abstract] [Full text] [PDF]


Graphic abstract

Review
A systemic review on development of mesoporous nanoparticles as a vehicle for transdermal drug delivery
Praveen Kolimi, Sagar Narala, Ahmed Adel Ali Youssef, Dinesh Nyavanandi, Narendar Dudhipala
Nanotheranostics 2023; 7(1): 70-89. doi:10.7150/ntno.77395
[Abstract] [Full text] [PDF]


Graphic abstract

Review
Nanofiber scaffolds based on extracellular matrix for articular cartilage engineering: A perspective
Elham Ahmadian, Aziz Eftekhari, Dawid Janas, Parviz Vahedi
Nanotheranostics 2023; 7(1): 61-69. doi:10.7150/ntno.78611
[Abstract] [Full text] [PDF]


Graphic abstract

Research Paper
Ultra-small NIR-Responsive Nanotheranostic Agent for Targeted Photothermal Ablation Induced Damage-Associated Molecular Patterns (DAMPs) from Post-PTT of Tumor Cells Activate Immunogenic Cell Death
Shankar Sobhana, Namratha Partha Sarathy, Laxmanan Karthikeyan, Krishnamurthy Shanthi, Raju Vivek
Nanotheranostics 2023; 7(1): 41-60. doi:10.7150/ntno.76720
[Abstract] [Full text] [PDF]


Graphic abstract

Research Paper
Image-Guided Nanodelivery of Pt(IV) Prodrugs to GRP-Receptor Positive Tumors
Francisco Silva, Carolina Mendes, Alice D'Onofrio, Maria Paula Cabral Campello, Fernanda Marques, Teresa Pinheiro, Kyle Gonçalves, Sérgio Figueiredo, Lurdes Gano, Mauro Ravera, Elisabetta Gabano, António Paulo
Nanotheranostics 2023; 7(1): 22-40. doi:10.7150/ntno.78807
[Abstract] [Full text] [PDF]


Graphic abstract

Research Paper
A Rapid, Convergent Approach to the Identification of Exosome Inhibitors in Breast Cancer Models
Zoraida Andreu, Esther Masiá, David Charbonnier, María J. Vicent
Nanotheranostics 2023; 7(1): 1-21. doi:10.7150/ntno.73606
[Abstract] [Full text] [PDF]

More ...

Editor-in-Chief:
Jonathan Lovell, PhD
Associate Professor, Biomedical Engineering
University at Buffalo, State University of New York
Special Issue: Interventional Nanotheranostics for targeted imaging and combination therapeutics. Guest Editor: Rajendra Prasad, PhD, MRSC, Department of Mechanical Engineering, Tufts University.
Nanotheranostics is now indexed in the Web of Science, Biological Abstracts and BIOSIS Previews.

Nanotheranostics has been selected by The Literature Selection Technical Review Committee (LSTRC) for inclusion in MEDLINE, the prestigious index of U.S. National Library of Medicine.

Gold nanorods (GNRs) have attracted great interest for photo-mediated biomedicines due to their tunable and high optical absorption, high photothermal conversion efficiency and facile surface modifiability. GNRs that have efficient absorption in second near-infrared (NIR-II) window hold further promise in bio-applications due to low background signal from tissue and deep tissue penetration. However, bare GNRs readily undergo shape deformation (termed as 'melting effect') during the laser illumination losing their unique localized surface plasmon resonance (LSPR) properties, which subsequently leads....
'See what you treat and treat what you see, at a molecular level', could be the motto of theranostics. The concept implies diagnosis (imaging) and treatment of cells (usually cancer) using the same molecule, thus guaranteeing a targeted cytotoxic approach of the imaged tumor cells while sparing healthy tissues. As the brilliant late Sam Gambhir would say, the imaging agent acts like a 'molecular spy' and reveals where the tumoral cells are located and the extent of disease burden (diagnosis). For treatment, the same 'molecular spy' docks to the same tumor cells, this time delivering cytotoxic doses....
Cognitive impairment is a common aspect of multiple sclerosis (MS) for which there are no treatments. Reduced brain N-acetylaspartylglutamate (NAAG) levels are linked to impaired cognition in various neurological diseases, including MS. NAAG levels are regulated by glutamate carboxypeptidase II (GCPII), which hydrolyzes the neuropeptide to N-acetyl-aspartate and glutamate. GCPII activity is upregulated multifold in microglia following neuroinflammation. Although several GCPII inhibitors, such as 2-PMPA, elevate brain NAAG levels and restore cognitive function in preclinical studies when given at....
Rationale: To assess treatment effects of 4 complementary miRNAs (miRNA-100/miRNA-122/antimiRNA-10b/antimiRNA-21) encapsulated in a biodegradable PLGA-PEG nanoparticle, administered by an ultrasound-guided microbubble-mediated targeted delivery (UGMMTD) approach in mouse models of hepatocellular carcinoma (HCC). Methods: In vitro apoptotic index was measured in HepG2 and Hepa1-6 HCC cells treated with various combinations of the 4 miRNAs with doxorubicin. Three promising combinations were further tested in vivo by using UGMMTD. 63 HepG2 xenografts in mice were randomized into: group 1, miRNA-122/antimiRNA-10b/antimiRNA-21/US/doxorubicin;....
Congratulations to Dr. Chen for being elected as AIMBE fellow.